Advaccine Biopharmaceuticals Suzhou Co., Ltd
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Advaccine Biopharmaceuticals Suzhou Co., Ltd
The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.
Soon after Zydus Cadila won a historic accelerated approval in India for the world’s first plasmid DNA vaccine for human use, in this case against COVID-19, Inovio’s candidate is set to move to Phase III in Brazil. But will the new technology find wide acceptance?
A plasmid DNA vaccine for human use has moved a step closer to reality, with Zydus Cadila applying for an accelerated nod for its COVID-19 candidate in India. 67% efficacy reported in an interim data readout and Delta variant being the prominent strain during a Phase III trial imply better odds for approval.
Inovio looks to countries outside the US to continue late-stage development of its vaccine, while a South Korean firm strikes a supply deal with Indonesia and Japan approves a new drug for COVID-19.
- Other Names / Subsidiaries
- Beijing Advaccine Biotechnology Co., Ltd
- Advaccine Clinical Research Pty Ltd
- Advaccine Shenzhen Biotechnology Co., Ltd
- Advanced Vaccine Laboratories Pty Ltd
- Suzhou Advaccine
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.